How should cardiac clearance be obtained for a patient with severe aortic stenosis and cardiomyopathy with a left‑ventricular ejection fraction of 35%?

Cardiac Clearance for Severe Aortic Stenosis with EF 35%

This patient requires aortic valve replacement (AVR) before proceeding with elective noncardiac surgery, as symptomatic severe AS with reduced LVEF (<50%) carries prohibitive perioperative risk without valve intervention. 1, 2, 3

Risk Stratification

This patient falls into a high-risk category with two critical features:

• Severe aortic stenosis (hemodynamically significant obstruction)
• Reduced LVEF of 35% (significantly below the 50% threshold)

The combination represents classical low-flow, low-gradient AS with reduced LVEF (Stage D2) 2, which carries substantially elevated perioperative mortality for noncardiac surgery without valve correction 1, 3.

Pre-Operative Assessment Required

1. Confirm AS Severity

Obtain echocardiography within 1 year if not already done 1:

• Aortic valve area (AVA) <1.0 cm²
• Mean gradient (may be <40 mmHg due to low flow state)
• Peak velocity (may be <4.0 m/s due to reduced stroke volume)

2. Dobutamine Stress Echocardiography

Perform low-dose dobutamine stress echo to differentiate true severe AS from pseudo-stenosis 4, 2:

• If velocity increases to ≥4.0 m/s or mean gradient ≥40 mmHg with AVA ≤1.0 cm² at any dobutamine dose = true severe AS → AVR indicated (Class IIa) 2
• Assess for contractile reserve (stroke volume increase >20%): presence indicates lower operative mortality and better long-term prognosis 4

3. Assess Viability

Determine if reduced EF is due to:

• Excessive afterload (reversible with AVR) - look for severe valve calcification on CT
• Myocardial scar (irreversible) - consider cardiac MRI to assess transmural scar extent 4

Patients with >10% viable myocardium are more likely to benefit from intervention 4.

Management Algorithm

For Elective Noncardiac Surgery:

Step 1: Determine if patient is symptomatic

• Exertional dyspnea, angina, heart failure, syncope, or presyncope 3

Step 2: If symptomatic OR LVEF <50% (this patient):

• Delay noncardiac surgery if possible
• Proceed with AVR first (Class I recommendation) 2, 3
• Choose between SAVR vs TAVI based on surgical risk assessment and Heart Team discussion 5, 3

Step 3: If noncardiac surgery cannot be delayed:

• Consider balloon aortic valvuloplasty (BAV) as bridge to definitive surgery 5, 3
• Proceed with elevated-risk surgery only if absolutely necessary with:
  • Intensive intraoperative hemodynamic monitoring 1
  • Careful fluid management (avoid hypovolemia and excessive volume shifts) 5
  • Heart rate control (avoid tachycardia) 5
  • Consider transesophageal echocardiography monitoring 5
• Discuss nonsurgical management, minimally invasive alternatives, or palliative care if patient not candidate for AVR 3

For Urgent/Emergency Noncardiac Surgery:

If surgery cannot be delayed:

• Perform under careful hemodynamic monitoring 1, 5
• Consider BAV as bridging strategy before elevated-risk procedures 3
• Optimize medical therapy for heart failure, though vasodilators (ACE inhibitors, ARBs) must be used with extreme caution due to risk of severe hypotension in severe AS 4

Critical Pitfalls to Avoid

1. Do NOT proceed with elective elevated-risk noncardiac surgery without addressing the valve - mortality is unacceptably high (4.3% 30-day mortality in one study) 3

2. Do NOT assume low gradients mean non-severe AS - with EF 35%, this is likely true severe AS with low-flow state requiring dobutamine stress echo confirmation 2

3. Do NOT delay AVR waiting for "optimal" medical optimization - optimization should not delay surgical decision-making 4

4. Do NOT use aggressive vasodilator therapy without extreme caution - can cause catastrophic hypotension 4

5. Avoid hypotension, excessive hypertension, and tachycardia during any procedure 3

Multidisciplinary Team Involvement

Mandatory Heart Team discussion including 5, 3:

• Cardiology (heart failure specialist and valvular disease specialist)
• Cardiac surgery
• Anesthesiology
• Surgical team for planned noncardiac procedure

Evidence Strength

The recommendation for AVR before elective noncardiac surgery in symptomatic severe AS or AS with reduced LVEF is supported by Class I, Level B evidence 2. Patients with prior AVR have dramatically reduced perioperative MACE (5.4% vs 20.5%, p<0.001) compared to untreated severe AS 3. Even among patients with severely reduced LVEF (<35%), AVR improves survival 6.